Key regions: France, Europe, United Kingdom, Brazil, India
Suriname, a small country located in South America, has been experiencing a growing demand for oncology drugs in recent years.
Customer preferences: The rising incidence of cancer cases in Suriname has led to an increase in demand for oncology drugs. Patients are seeking effective treatments to combat the disease, and are willing to pay a premium for the latest and most advanced drugs available in the market. Additionally, there is a growing trend towards personalized medicine, where treatments are tailored to the individual patient's genetic makeup, leading to a higher demand for precision oncology drugs.
Trends in the market: The oncology drugs market in Suriname is witnessing a shift towards targeted therapies and immunotherapies. These treatments are designed to target specific cancer cells and boost the body's immune system to fight the disease. This trend is driven by the need for more effective and less toxic treatments, as well as the growing understanding of the genetic basis of cancer.
Local special circumstances: One of the unique characteristics of the oncology drugs market in Suriname is the high cost of drugs. Due to the small size of the market and limited purchasing power of the population, drug manufacturers are often reluctant to introduce their latest and most expensive drugs in the country. This has led to a situation where patients often have to travel abroad to receive the latest treatments, which can be a significant financial burden.
Underlying macroeconomic factors: The overall economic development of Suriname is a key factor affecting the oncology drugs market. The country has been experiencing a period of economic growth in recent years, driven by its natural resources. However, this growth has been unevenly distributed, with a large portion of the population still living in poverty. This has led to a situation where access to healthcare and expensive drugs is limited for a significant portion of the population. Additionally, the country's healthcare system is still developing, and there are challenges related to infrastructure, staffing, and funding. These factors can impact the availability and affordability of oncology drugs in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
